MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
43.25
+2.23 (5.44%)
Apr 23, 2024, 4:00 PM EDT - Market closed

MLTX Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current2023202220212020
Market Capitalization
2,7013,771553146168
Market Cap Growth
-581.49%277.92%-13.02%-
Enterprise Value
2,1943,264482153167
PE Ratio
-85.55-85.55-8.58-2.73-1853.11
PB Ratio
5.457.6111.32-12.57-66.90
P/FCF Ratio
-87.57-87.57-9.90-4.16-531.53
P/OCF Ratio
-88.16-88.16-9.90-4.16-531.53
EV/EBITDA Ratio
-74.23-74.23-7.47-2.86-1839.04
EV/EBIT Ratio
-74.20-74.20-7.47-2.86-1839.04
EV/FCF Ratio
-75.79-75.79-8.61-4.35-527.50
Debt / Equity Ratio
0.010.010.01-1.29-0.02
Debt / EBITDA Ratio
-0.08-0.080.00-0.28-0.64
Debt / FCF Ratio
-0.09-0.09-0.01-0.43-0.18
Quick Ratio
51.3851.389.440.3910.67
Current Ratio
51.5951.599.980.4612.93
Return on Equity (ROE)
-12.10%-12.10%-181.20%3310.30%-
Return on Assets (ROA)
-11.00%-11.00%-93.60%-59.80%-
Return on Capital (ROIC)
-10.84%-10.84%-132.29%-1596.93%4.30%
Earnings Yield
-1.63%-1.17%-11.66%-36.64%-0.05%
FCF Yield
-1.59%-1.14%-10.10%-24.06%-0.19%
Buyback Yield / Dilution
-67.30%-67.30%87.40%-2510.73%-
Total Shareholder Return
-67.30%-67.30%87.40%-2510.73%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).